Search results for " STEATOSIS"

showing 10 items of 63 documents

Science to Practice: Should Biopsy Be Performed in Potential Liver Donors When Unenhanced CT Shows an Unacceptable Degree of Steatosis for Transplant…

2006

Park et al (1) have demonstrated that unenhanced CT can accurately depict moderate to severe (ie, ≥30%) macrovesicular steatosis, thereby allowing avoidance of biopsy in potential living liver donors who have an unacceptable degree of steatosis for transplantation. Biopsy will still be needed in donors with macrovesicular steatosis of less than 30% at unenhanced CT to rule out occult chronic liver disease and more severe steatosis that is undetected at CT. © RSNA, 2006.

Moderate to severemedicine.medical_specialtymedicine.diagnostic_testbusiness.industryBiopsyChronic liver diseasemedicine.diseaseMacrovesicular steatosisOccultLiver TransplantationFatty LiverTransplantationLiverBiopsyLiver donorsLiving DonorsmedicineHumansRadiology Nuclear Medicine and imagingRadiologySteatosisTomography X-Ray ComputedbusinessRadiology
researchProduct

Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: From a Clinical to a Molecular Association

2009

Hepatocellular carcinoma (HCC) is the most frequent primary neoplasm of the liver, and is the fourth most common malignancy worldwide. It is also the third leading cause of cancer-related deaths. Most cases of HCC develop on a pre-existing chronic liver disease, usually due to hepatitis C virus (HCV), hepatitis B virus (HBV), or alcohol. However, between 15% and 50% of HCC develops in the absence of a known etiology of liver disease, and different lines of evidence identify in non-alcoholic fatty liver disease (NAFLD) a possible relevant risk factor for occurrence of HCC. Insulin resistance (IR), steatosis, oxidative stress and imbalances in adipokine/cytokine interplay, the most important …

Pathologymedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusmedicine.disease_causeChronic liver diseaseLiver diseaseRisk FactorsDrug DiscoveryDiabetes MellitusmedicineAnimalsHumansObesityLiver Diseases AlcoholicPharmacologyHepatitis B virusSettore MED/12 - Gastroenterologiabusiness.industryLiver NeoplasmsFatty livermedicine.diseasedigestive system diseasesFatty LiverHepatocellular carcinomaCancer researchnafld hepatocellular carcinoma steatosisSteatosisbusinessLiver cancerCurrent Pharmaceutical Design
researchProduct

IMPACT OF NON-ALCOHOLIC FATTY LIVER DISEASE ON CARDIOVASCULAR RISK IN A GENERAL POPULATION

2019

Background: Background:Nonalcoholic fatty liver (NAFL) is a major cause of liver disease worldwide leading also to a higher risk of cardiovascular events. We aimed to evaluate the impact of fatty liver and fibrosis on cardiovascular risk factors in a general population. Methods: 604 subjects included in the community-based ABCD (Alimentazione, Benessere Cardiovascolare e Diabete) study were recruited. Steatosis (CAP >288 dB/m) and fibrosis (> 8.7 KPa by M and > 7.2 KPa by XL probe) were assessed with FibroScan Cardiovascular risk was evaluated by the Atherosclerotic Cardiovascular Disease (ASCVD) risk estimator and de ned low if <5%, borderline if 5%-7 4%, intermediate if 7-9% a…

obesity diabetes steatosis ABCD study fatty liver disease
researchProduct

Curcumin and Andrographolide Co-Administration Safely Prevent Steatosis Induction and ROS Production in HepG2 Cell Line

2023

Non-alcoholic fatty liver disease (NAFLD) is an emerging chronic liver disease worldwide. Curcumin and andrographolide are famous for improving hepatic functions, being able to reverse oxidative stress and release pro-inflammatory cytokines, and they are implicated in hepatic stellate cell activation and in liver fibrosis development. Thus, we tested curcumin and andrographolide separately and in combination to determine their effect on triglyceride accumulation and ROS production, identifying the differential expression of genes involved in fatty liver and oxidative stress development. In vitro steatosis was induced in HepG2 cells and the protective effect of curcumin, andrographolide, and…

lipid dropletsOrganic ChemistryandrographolidePharmaceutical ScienceGKROSAnalytical Chemistryliver steatosisSettore BIO/13 - Biologia ApplicataChemistry (miscellaneous)NAFLDDrug DiscoveryPPARGC1Aliver steatosis.Molecular MedicineFABP1curcuminPhysical and Theoretical ChemistryMolecules
researchProduct

Focal hepatic intrinsically hyperattenuating lesions at unenhanced CT: Not always calcifications.

2021

Due to the growing use of CT, there has been an increase in the frequency of detecting focal liver lesions. Intrinsically hyperattenuating hepatic lesions or pseudolesions are not uncommon at unenhanced CT. Hyperattenuating hepatic lesions can be divided into non-calcified and calcified. Causes of intrinsic hyperattenuation include hemorrhage, thrombosis, and calcifications. Focal liver lesions can show hyperattenuation on unenhanced CT in case of severe liver steatosis. Recognition of etiologies associated with hyperattenuation on unenhanced CT can help the radiologist in characterizing focal liver lesions and pseudolesions. In this paper, we describe the spectrum of intrinsically hyperatt…

medicine.medical_specialtybusiness.industryHyperattenuating hepatic pseudolesionLiver NeoplasmsCalcinosismedicine.diseaseThrombosisUnenhanced CTHepatic calcified lesionsDiagnosis DifferentialFatty LiverLiver steatosisIntrinsically hyperattenuating hepatic lesionLiver calcificationsmedicineHumansRadiology Nuclear Medicine and imagingRadiologyLiver calcificationsbusinessTomography X-Ray ComputedClinical imaging
researchProduct

Is there a link between liver steatosis, carotid atherosclerosis and C-reactive protein in metabolic and non-metabolic patients?

2008

Carotid atherosclerosismedicine.medical_specialtybiologybusiness.industryC-reactive proteinGeneral MedicineEndocrinologyLiver steatosisInternal medicineInternal Medicinemedicinebiology.proteinCardiology and Cardiovascular Medicinebusiness
researchProduct

Chemotherapy and Hepatic Steatosis: Impact on Postoperative Morbidity and Survival after Liver Resection for Colorectal Liver Metastases

2020

<b><i>Background:</i></b> Hepatic steatosis and chemotherapy in the treatment of colorectal liver metastases (CLM) are often linked to increased mortality and morbidity after liver resection. This study evaluates the influence of macrovesicular hepatic steatosis and chemotherapeutic regimes on graded morbidity and mortality after liver resection for CLM. <b><i>Methods:</i></b> A total of 323 cases of liver resection for CLM were retrospectively analysed using univariable and multivariable linear, ordinal and Cox regression analyses. The resected liver tissue was re-evaluated by a single observer to determine the grade and type of hepatic steat…

Chemotherapymedicine.medical_specialtybusiness.industryProportional hazards modelColorectal cancermedicine.medical_treatmentGastroenterologymedicine.diseaseGastroenterologyOxaliplatinInternal medicineMedicineSurgerySteatosisRisk factorMacrovesicular hepatic steatosisbusinessPacked red blood cellsResearch Articlemedicine.drugVisceral Medicine
researchProduct

A Mediterranean Diet Rich in Extra-Virgin Olive Oil Is Associated with a Reduced Prevalence of Nonalcoholic Fatty Liver Disease in Older Individuals …

2019

Los autores de este trabajo forman parte de PREDIMED study investigators. Son los siguientes: Principales: Xavier Pintó, Marta Fanlo-Maresma, Emili Corbella, Xavier Corbella, M Teresa Mitjavila, Juan J Moreno, Rosa Casas, Ramon Estruch, Dolores Corella, Mònica Bulló, Miguel Ruiz-Canela, Olga Castañer, J Alfredo Martinez, Emilio Ros, PREDIMED Study Investigators. PREDIMED Study investigators: Estruch R, Martínez-González MA, Corella D, Fitó M, Ros E, Salas-Salvadó J, Arós F, Aldamiz-Echevarría M, Alonso-Gómez AM, Berjón J, Forga L, Gállego J, García-Layana A, Larrauri A, Portu-Zapirain J, Timiraos J, Ros E, Covas MI, Martínez-González MA, Salas-Salvadó J, Pérez-Heras A, Serra-Mir M, Pi-Sunye…

0301 basic medicineMalePREDIMEDMedicine (miscellaneous)030209 endocrinology & metabolismHepatic steatosisnutsDiet Mediterranean03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsMediterranean dietPrevalenceHumansDiet Fat-RestrictedDietary fatAged030109 nutrition & dieteticsNutrition and DieteticsPhilosophyMiddle AgedPredimedMagnetic Resonance ImagingPrimary PreventionEditorialLiverCardiovascular DiseasesSpainFemaleHumanitiesOlive oilOlive oilDietary fat
researchProduct

MRI as the new reference standard in quantifying liver steatosis: the need for international guidelines.

2012

We read with great interest the paper by Raptis et al 1 regarding the quantification of liver steatosis by chemical-shift MRI. Chemical-shift imaging takes advantage of the difference in resonance frequency between water and fat (more precisely methylene, the most abundant group in triglycerides) to differentiate them. The dual-echo (in-phase/out-of-phase) MR technique used by the authors and derived from one of their previously published papers2 neglects T2* decay and assumes that the signal difference is due to fat–water interference alone.3 Yet, liver iron …

Malemedicine.medical_specialtymedicine.diagnostic_testbusiness.industryFatty liverGastroenterologyMagnetic resonance imagingmedicine.diseaseLipidsMagnetic Resonance ImagingFatty LiverLiver steatosismedicineLiver ironAnimalsHumansFemaleRadiologybusinessNuclear medicineReference standardsGut
researchProduct

Upregulation of liver VLDL receptor and FAT/CD36 expressions in LDLR-/- apoB100/100 mice fed trans-10,cis-12 conjugated linoleic acid

2006

International audience; This study explores the mechanisms responsible for the fatty liver setup in mice fed trans-10,cis-12 conjugated linoleic acid (t10c12 CLA), hypothesizing that an induction of low density lipoprotein receptor (LDLR) expression is associated with lipid accumulation. To this end, the effects of t10c12 CLA treatment on lipid parameters, serum lipoproteins, and expression of liver lipid receptors were measured in LDLR(-/-) apoB(100/100) mice as a model of human familial hypercholesterolemia itself depleted of LDLR. Mice were fed t10c12 CLA over 2 or 4 weeks. We first observed that the treatment induced liver steatosis, even in the absence of LDLR. Mice treated for 2 weeks…

CD36 AntigensMaleVery low-density lipoproteinTRANSLOCASECD36RECEPTEUR SCAVENGER[SDV]Life Sciences [q-bio]FATTY ACID TRANSLOCASE030204 cardiovascular system & hematologyBiochemistryMice0302 clinical medicineEndocrinologyLinoleic Acids ConjugatedMice Knockout0303 health sciencesLipoprotein lipaselipoprotéinebiologyacide grasrécepteur d'hormoneChemistryFatty liverFatty Acidsfood and beveragesHEPATIC LIPASELipidsLOW DENSITY LIPOPROTEIN RECEPTOR3. Good healthUp-RegulationLiverSCAVENGER RECEPTOR CLASS B TYPE ILIVER STEATOSIS;LOW DENSITY LIPOPROTEIN RECEPTOR;TRIGLYCERIDE;LIPOATROPHY;LIPOPROTEIN;FATTY ACID TRANSLOCASE;VERY LOW DENSITY LIPOPROTEIN RECEPTOR;HEPATIC LIPASE;LIPOPROTEIN LIPASE;LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN;SCAVENGER RECEPTOR CLASS B TYPE I;LIPOATROPHIE;TRANSLOCASE;LIPASE HEPATIQUE;RECEPTEUR SCAVENGERApolipoprotein B-100lipoprotéine lipaseTRIGLYCERIDElipids (amino acids peptides and proteins)Oxidation-Reductionmedicine.medical_specialtyLIPASE HEPATIQUELipolysisVLDL receptorMice Transgenicacide linoléique conjugué03 medical and health sciencesstéatose hépatiqueInternal medicineLIVER STEATOSISmedicineLIPOPROTEIN LIPASEAnimalsRNA Messengerlipoprotéine de faible densite030304 developmental biologyLOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEINnutritional and metabolic diseasesCell Biologymedicine.diseaseLipid MetabolismLIPOATROPHYDietary FatsEndocrinologyLIPOPROTEINReceptors LDLVERY LOW DENSITY LIPOPROTEIN RECEPTORLIPOATROPHIELDL receptorbiology.proteinacide gras transHepatic lipaseLipoprotein
researchProduct